Adenovirus polynucleotides and polypeptides

Abstract

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1,(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

1 - 42 . (canceled) 
     
     
         43 . A recombinant chimpanzee adenovirus ChAd155 comprising a nucleic acid sequence encoding a heterologous protein wherein:
 (a) the E1 and E4 regions of chimpanzee adenovirus ChAd155 are deleted;   (b) E4orf6 of human adenovirus Ad5 is inserted;   (c) the nucleic acid sequence is operatively linked to one or more sequences which direct expression of said heterologous protein in a host cell; and   (d) the heterologous protein is an antigenic protein or fragment thereof derived from a virus and is selected from fusion protein (F), the attachment protein (G), the matrix protein (M2), and the nucleoprotein (N) of respiratory syncytial virus (RSV).   
     
     
         44 . A composition comprising the recombinant chimpanzee adenovirus ChAd155 vector according to  claim 43 , and a pharmaceutically acceptable excipient. 
     
     
         45 . The recombinant chimpanzee adenovirus ChAd155 according to  claim 43 , wherein the nucleic acid sequence encoding a heterologous protein encodes an RSV FΔTM antigen, an RSV M2-1 antigen and an N antigen. 
     
     
         46 . The recombinant chimpanzee adenovirus ChAd155 according to  claim 43 , wherein the nucleic acid sequence encoding a heterologous protein encodes a sequence according to SEQ ID NO: 37. 
     
     
         47 . The recombinant chimpanzee adenovirus ChAd155 according to  claim 43 , wherein the recombinant adenovirus is replication-incompetent. 
     
     
         48 . The recombinant chimpanzee adenovirus ChAd155 according to  claim 43 , wherein the adenovirus is capable of infecting a mammalian cell. 
     
     
         49 . The composition according to  claim 44 , further comprising at least one adjuvant selected from inorganic adjuvants, organic adjuvants, oil-based adjuvants, cytokines, particulate adjuvants, virosomes, bacterial adjuvants, synthetic adjuvants, synthetic polynucleotides adjuvants, and immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides (“CpG”). 
     
     
         50 . The composition according to  claim 49 , wherein the adjuvant is a 3D-MPL, QS21, or a mixture thereof. 
     
     
         51 . A method of treatment or prophylaxis of respiratory syncytial virus (RSV) infection comprising administering to a patient in need thereof the recombinant chimpanzee vector ChAd155, of  claim 43 . 
     
     
         52 . A method of treatment or prophylaxis of respiratory syncytial virus (RSV) infection comprising administering to a patient in need thereof the composition of  claim 44 . 
     
     
         53 . An isolated polynucleotide comprising the sequence of SEQ ID NO: 11.